Liposomes for inhalation

Hui Xin Ong*, Daniela Traini, Paul Young

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Inhalation of liposomes formulated with phospholipids similar to endogenous lung surfactants and lipids offers biocompatibility and versatility within the pulmonary medicine field to treat a range of diseases such as lung cancer, cystic fibrosis and lung infections. Manipulation of the physicochemical properties of liposomes enables innovative design of the carrier to meet specific delivery, release and targeting requirements. This delivery system offers several benefits: improved pharmacokinetics with reduced toxicity, enhanced therapeutic efficacy, increased delivery of poorly soluble drugs, taste masking, biopharmaceutics degradation protection and targeted cellular therapy. This section provides an overview of liposomal formulation and delivery, together with their applications for different disease states in the lung.
Original languageEnglish
Title of host publicationISAM textbook of aerosol medicine
EditorsRajiv Dhand, Beth Rothen-Rutishauser, Anthony J. Hickey
Place of PublicationUnited States
PublisherMary Ann Liebert, Inc., publishers
Number of pages27
ISBN (Electronic)9780996371100
Publication statusPublished - 2015
Externally publishedYes


  • liposomes
  • antibiotics
  • inhalation
  • respiratory disease
  • controlled release


Dive into the research topics of 'Liposomes for inhalation'. Together they form a unique fingerprint.

Cite this